PCIDB

KNApSAcK Metabolite C00010876

Metabolite

KNApSAcK Entry

id C00010876
Name Thymoquinone / p-Mentha-3,6-diene-2,5-dione
CAS RN 490-91-5
Standard InChI InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3
Standard InChI (Main Layer) InChI=1S/C10H12O2/c1-6(2)8-5-9(11)7(3)4-10(8)12/h4-6H,1-3H3

Cluster

Phytochemical cluster
KCF-S cluster No. 7863

Link

ChEMBL

By standard InChI CHEMBL1672002
By standard InChI Main Layer CHEMBL1672002

KEGG

By LinkDB

CTD

By CAS RN C003466

Human Protein / Gene in interaction

CTD interaction (2)

compound gene gene name gene description interaction interaction type form reference
pmid
C003466 596 BCL2
Bcl-2
PPP1R50
B-cell CLL/lymphoma 2 thymoquinone results in decreased expression of BCL2 protein decreases expression
protein 21609759
C003466 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 thymoquinone results in increased expression of TP53 protein increases expression
protein 21609759

Related Disease

Diseases related to CTD interactions

15 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000419 C003466 Albuminuria therapeutic
10755708
D001169 C003466 Arthritis, Experimental therapeutic
22450443
D001172 C003466 Arthritis, Rheumatoid therapeutic
22450443
D002286 C003466 Carcinoma, Ehrlich Tumor therapeutic
10619376
D003921 C003466 Diabetes Mellitus, Experimental therapeutic
21382363
D003928 C003466 Diabetic Nephropathies therapeutic
19484499
D056486 C003466 Drug-Induced Liver Injury therapeutic
22293407
D064420 C003466 Drug-Related Side Effects and Adverse Reactions therapeutic
9700580
D005198 C003466 Fanconi Syndrome therapeutic
10619376
D006973 C003466 Hypertension therapeutic
17236176
D007249 C003466 Inflammation therapeutic
12065147
D008206 C003466 Lymphatic Diseases therapeutic
22293407
D009374 C003466 Neoplasms, Experimental therapeutic
10619376
D011507 C003466 Proteinuria therapeutic
10755708
D011658 C003466 Pulmonary Fibrosis therapeutic
22982510